Company: RGNX
Filing Date: 2025-11-26
Form Type: S-3
Source: 0001193125-25-300539
Chunk: 20

Company: REGENXBIO Inc.
Filing Date: 2025-11-26
Form: S-3
Chunk 20
---
| • |     | if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; |

| • |     | whether the warrants represented by the warrant certificates or debt securities that may be issued upon exercise 
 of the warrants will be issued in registered or bearer form;                                                     |

| • |     | information relating to book-entry procedures, if any; |

| • |     | the currency or currency units in which the offering price, if any, and the exercise price are payable; |

| • |     | if applicable, a discussion of material U.S. federal income tax considerations; |

| • |     | anti-dilution provisions of the warrants, if any; |

| • |     | redemption or call provisions, if any, applicable to the warrants; |

| • |     | information with respect to book-entry procedures; |

| • |     | identity of the warrant agent, if any; and |

| • |     | any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and 
 exercise of the warrants.                                                                                      |

Exercise of Warrants Each holder of a warrant will be entitled to purchase, at the exercise price set forth in the applicable prospectus supplement, the number of shares of common stock, shares of preferred stock or the principal amount of debt securities being offered. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants are void. Holders may exercise warrants as set forth in the prospectus supplement relating to the warrants being offered. 12

Until a holder exercises the warrants to purchase our shares of common stock, shares of
preferred stock or debt securities, the holder will not have any rights as a holder of our shares of common stock, shares of preferred stock or debt securities, as the case may be, by virtue of ownership of warrants, including, with respect to
equity warrants, any right to vote, consent, receive dividends, or receive notice as stockholders with respect to any meeting of the stockholders for the election of directors or any other matter and with respect to debt warrants, any right to
receive payment of principal or premium, if any, or interest on the debt securities purchasable upon exercise.

13

DESCRIPTION OF DEBT SECURITIES We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, debt